MCID: DMY001
MIFTS: 46

Demyelinating Polyneuropathy

Categories: Immune diseases, Muscle diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Demyelinating Polyneuropathy

MalaCards integrated aliases for Demyelinating Polyneuropathy:

Name: Demyelinating Polyneuropathy 12 15
Peripheral Demyelinating Neuropathy 12 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5214
NCIt 50 C27062
SNOMED-CT 68 23414001
UMLS 73 C0270922

Summaries for Demyelinating Polyneuropathy

MalaCards based summary : Demyelinating Polyneuropathy, also known as peripheral demyelinating neuropathy, is related to chronic inflammatory demyelinating polyneuropathy and guillain-barre syndrome. An important gene associated with Demyelinating Polyneuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are Neuroscience and L1CAM interactions. The drugs Antibodies and gamma-Globulins have been mentioned in the context of this disorder. Affiliated tissues include t cells, spinal cord and b cells, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Demyelinating Polyneuropathy

Diseases in the Demyelinating Polyneuropathy family:

Chronic Inflammatory Demyelinating Polyneuropathy Subacute Inflammatory Demyelinating Polyneuropathy

Diseases related to Demyelinating Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 259)
# Related Disease Score Top Affiliating Genes
1 chronic inflammatory demyelinating polyneuropathy 34.0 AIF1 CNTN2 HP NFASC TTR
2 guillain-barre syndrome 32.6 ALB HP PMP22
3 polyneuropathy 32.1 MAG PMP22 TTR
4 multifocal motor neuropathy 30.6 CNTN2 FCGR2B
5 sensory peripheral neuropathy 30.0 MAG NGF PMP22
6 chronic inflammatory demyelinating polyradiculoneuropathy 29.9 ALB NFASC PMP22
7 polyradiculoneuropathy 29.5 ALB CNTN1 MAG NFASC PMP22
8 peripheral nervous system disease 29.2 ALB MAG NFASC NGF PMP22 TTR
9 peripheral demyelinating neuropathy, central dysmyelination, waardenburg syndrome, and hirschsprung disease 12.8
10 subacute inflammatory demyelinating polyneuropathy 12.4
11 guillain-barre syndrome, familial 12.0
12 lewis-sumner syndrome 11.5
13 charcot-marie-tooth disease, axonal, type 2e 11.4
14 canomad syndrome 11.2
15 charcot-marie-tooth disease, demyelinating, type 1b 11.1
16 charcot-marie-tooth disease, axonal, type 2a1 11.1
17 charcot-marie-tooth disease, demyelinating, type 1a 11.1
18 charcot-marie-tooth disease and deafness 11.1
19 charcot-marie-tooth disease, type 4a 11.1
20 charcot-marie-tooth disease, x-linked dominant, 6 11.1
21 charcot-marie-tooth disease, x-linked dominant, 1 11.1
22 charcot-marie-tooth disease, x-linked recessive, 5 11.1
23 charcot-marie-tooth disease, axonal, type 2b 11.1
24 charcot-marie-tooth disease, demyelinating, type 1c 11.1
25 neuropathy, hereditary motor and sensory, type via 11.1
26 charcot-marie-tooth disease, type 4b1 11.1
27 charcot-marie-tooth disease, type 4d 11.1
28 charcot-marie-tooth disease, axonal, type 2d 11.1
29 charcot-marie-tooth disease, type 4c 11.1
30 charcot-marie-tooth disease, type 4b2 11.1
31 charcot-marie-tooth disease, axonal, type 2b1 11.1
32 charcot-marie-tooth disease, axonal, type 2b2 11.1
33 hereditary motor and sensory neuropathy, type iic 11.1
34 charcot-marie-tooth disease, dominant intermediate b 11.1
35 charcot-marie-tooth disease, axonal, type 2f 11.1
36 charcot-marie-tooth disease, axonal, type 2i 11.1
37 charcot-marie-tooth disease, demyelinating, type 1d 11.1
38 charcot-marie-tooth disease, demyelinating, type 1f 11.1
39 charcot-marie-tooth disease, axonal, type 2j 11.1
40 charcot-marie-tooth disease, axonal, type 2k 11.1
41 charcot-marie-tooth disease, axonal, type 2l 11.1
42 charcot-marie-tooth disease, axonal, autosomal dominant, type 2a2a 11.1
43 charcot-marie-tooth disease, type 4h 11.1
44 charcot-marie-tooth disease, axonal, type 2n 11.1
45 charcot-marie-tooth disease, axonal, type 2o 11.1
46 charcot-marie-tooth disease, axonal, type 2p 11.1
47 charcot-marie-tooth disease, demyelinating, type 4f 11.1
48 charcot-marie-tooth disease, axonal, type 2q 11.1
49 charcot-marie-tooth disease, type 4b3 11.1
50 charcot-marie-tooth disease, axonal, type 2r 11.1

Graphical network of the top 20 diseases related to Demyelinating Polyneuropathy:



Diseases related to Demyelinating Polyneuropathy

Symptoms & Phenotypes for Demyelinating Polyneuropathy

MGI Mouse Phenotypes related to Demyelinating Polyneuropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.85 APOA4 CNTN1 CNTN2 FCGR2B FYB1 MAG
2 homeostasis/metabolism MP:0005376 9.73 AIF1 ALB APOA4 FCGR2B FYB1 HP
3 nervous system MP:0003631 9.32 AIF1 APOA4 CNTN1 CNTN2 FCGR2B MAG

Drugs & Therapeutics for Demyelinating Polyneuropathy

Drugs for Demyelinating Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
2 gamma-Globulins Phase 4,Phase 3,Phase 2,Not Applicable
3 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Not Applicable
4 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Not Applicable
7 Immunoglobulin G Phase 4,Phase 3,Not Applicable
8
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
9 tannic acid Approved Phase 3
10
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
11
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
12 Anti-Inflammatory Agents Phase 3,Phase 1,Phase 2
13 Hormone Antagonists Phase 3,Phase 1,Phase 2
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2
15 glucocorticoids Phase 3,Phase 1,Phase 2
16 Hormones Phase 3,Phase 1,Phase 2
17 Antineoplastic Agents, Hormonal Phase 3,Phase 1,Phase 2
18 3,4-diaminopyridine Phase 3
19 Potassium Channel Blockers Phase 3
20 Pharmaceutical Solutions Phase 3
21
rituximab Approved Phase 2,Phase 1 174722-31-7 10201696
22
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
23
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
24
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
25
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
26
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2 6055-19-2, 50-18-0 2907
27
Mesna Approved, Investigational Phase 1, Phase 2 3375-50-6 598
28
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
30
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
31 Antioxidants Phase 2
32 Vitamin B9 Phase 2
33 Vitamins Phase 2
34 Protective Agents Phase 2,Phase 1
35 Thioctic Acid Phase 2
36 Trace Elements Phase 2
37 Alpha-lipoic Acid Phase 2
38 Folate Phase 2
39 Vitamin B Complex Phase 2
40 Micronutrients Phase 2
41 Antirheumatic Agents Phase 2,Phase 1
42 Antibodies, Monoclonal Phase 2,Phase 1
43 Krestin Phase 1, Phase 2
44 Adjuvants, Immunologic Phase 1, Phase 2
45 Methylprednisolone acetate Phase 1, Phase 2
46 Antineoplastic Agents, Alkylating Phase 1, Phase 2,Phase 2
47 Antilymphocyte Serum Phase 1, Phase 2
48 Prednisolone acetate Phase 1, Phase 2
49 Neuroprotective Agents Phase 1, Phase 2
50 Immunosuppressive Agents Phase 1, Phase 2,Phase 2

Interventional clinical trials:

(show all 44)
# Name Status NCT ID Phase Drugs
1 IVIg for Demyelination in Diabetes Mellitus Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
3 Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Not yet recruiting NCT03684018 Phase 4
4 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
5 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
6 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
7 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
8 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
9 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
10 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
11 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
12 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
13 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
14 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy Recruiting NCT02638207 Phase 3 NewGam
15 Panzyga in CIDP Administered at Different Infusion Rates Not yet recruiting NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
16 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Unknown status NCT02967679 Phase 1, Phase 2 MD1003
17 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00962429 Phase 2 lipoic acid
18 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
19 Rituximab to Treat Neuropathy With Anti-MAG Antibodies Completed NCT00050245 Phase 2 Rituximab
20 Stem Cell Transplantation for Stiff Person Syndrome (SPS) Recruiting NCT02282514 Phase 1, Phase 2 Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF;Rituxan
21 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT00278629 Phase 2
22 Thrombolysis in Ischemic Spinal Cord Stroke Active, not recruiting NCT02242084 Phase 2 Intravenuse Alteplase
23 High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
24 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
25 Effects of an Intervention Program by Proprioceptive Neuromuscular Facilitation, in Muscle Force Irradiation. Unknown status NCT02255708 Phase 1
26 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT01379833
27 sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN Unknown status NCT02271724
28 sCD163 as a Potential Biomarker in Guillain- Barré Syndrome Unknown status NCT02582853
29 Effect of Resistance and Aerobic Exercise in CIDP or MMN Completed NCT02121678 Not Applicable
30 Prevalence of Genetic Mutations in Patients With Neuropathy Associated With Anti-Myelin-associated Glycoprotein (MAG) Antibodies Completed NCT03268161
31 Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC) Completed NCT03460951
32 Immunoglobulin Dosage and Administration Form in CIDP and MMN Completed NCT02111590 Immunoglobulins
33 Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom Completed NCT01953822
34 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
35 Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP Recruiting NCT03779828
36 Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuropathy With Antibody A MAG Recruiting NCT03008733 Not Applicable
37 Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology Recruiting NCT03373370
38 Low Level Laser Therapy Effects in Peripheral Nerves Patient With Leprosy. Recruiting NCT03072004 Not Applicable
39 IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements Active, not recruiting NCT02414490 Intravenous Immunoglobulin
40 Subcutaneous Immunoglobulin for CIDP Active, not recruiting NCT02465359 Not Applicable Immune Globulin Subcutaneous (Human)
41 Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Not yet recruiting NCT03772717 Not Applicable Standard of Care
42 Quantification of Nerve Stiffness in Neuropathies Not yet recruiting NCT03397303 Not Applicable
43 A Natural History Study of Charcot-Marie-Tooth 4J (CMT4J) Not yet recruiting NCT03810508
44 Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome Terminated NCT00004833 Not Applicable Immune globulin

Search NIH Clinical Center for Demyelinating Polyneuropathy

Genetic Tests for Demyelinating Polyneuropathy

Anatomical Context for Demyelinating Polyneuropathy

MalaCards organs/tissues related to Demyelinating Polyneuropathy:

41
T Cells, Spinal Cord, B Cells, Skin, Heart, Thyroid, Myeloid

Publications for Demyelinating Polyneuropathy

Articles related to Demyelinating Polyneuropathy:

(show top 50) (show all 802)
# Title Authors Year
1
Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab. ( 29382383 )
2018
2
Chronic inflammatory demyelinating polyneuropathy misdiagnosis: A clinical more than electrophysiogical problem? ( 29406592 )
2018
3
Onset of fulminant type 1 diabetes mellitus under immunotolerance status after long-term therapy for chronic inflammatory demyelinating polyneuropathy. ( 29905029 )
2018
4
Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy. ( 29182448 )
2018
5
Octagam<sup>Ar</sup> for chronic inflammatory demyelinating polyneuropathy: results from three observational studies. ( 29517417 )
2018
6
A patient with peripheral demyelinating neuropathy, central dysmyelinating leukodystrophy, Waardenburg syndrome, and severe hypoganglionosis associated with a novel SOX10 mutation. ( 29681101 )
2018
7
Nocebo in chronic inflammatory demyelinating polyneuropathy; a systematic review and meta-analysis of placebo-controlled clinical trials. ( 29627036 )
2018
8
A novel paraneoplastic syndrome with acquired lipodystrophy and chronic inflammatory demyelinating polyneuropathy in an adolescent male with craniopharyngioma. ( 29455190 )
2018
9
Vestibular impairment in chronic inflammatory demyelinating polyneuropathy. ( 29260355 )
2018
10
Elevated serum levels of endothelin-1 in patients with chronic inflammatory demyelinating polyneuropathy. ( 29137897 )
2018
11
Standing postural reaction to visual and proprioceptive stimulation in chronic acquired demyelinating polyneuropathy. ( 29313871 )
2018
12
Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. ( 29968199 )
2018
13
Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients. ( 29603827 )
2018
14
Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. ( 29907605 )
2018
15
Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy. ( 29122522 )
2018
16
Neurofascin and Compact Myelin Antigen-Specific T Cell Response Pattern in Chronic Inflammatory Demyelinating Polyneuropathy Subtypes. ( 29615965 )
2018
17
Elevated leukocyte count in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy. ( 29341326 )
2018
18
Possible Combined Central and Peripheral Demyelination Presenting as Optic Neuritis, Cervical Myelitis, and Demyelinating Polyneuropathy with Marked Nerve Hypertrophy. ( 29540658 )
2018
19
Bilateral facial nerve palsies secondary to chronic inflammatory demyelinating polyneuropathy following adalimumab treatment. ( 29179036 )
2018
20
The ulnar ratio as a sensitive and specific marker of acute inflammatory demyelinating polyneuropathy. ( 29940481 )
2018
21
Drug-induced hypersensitivity syndrome followed by chronic inflammatory demyelinating polyneuropathy. ( 29671897 )
2018
22
High-resolution nerve ultrasound and magnetic resonance neurography as complementary neuroimaging tools for chronic inflammatory demyelinating polyneuropathy. ( 29552093 )
2018
23
Autoantibodies Against the Node of Ranvier in Seropositive Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic, Pathogenic, and Therapeutic Relevance. ( 29867996 )
2018
24
Does grip strength reflect isokinetic muscle strength in lower limbs in patients with chronic inflammatory demyelinating polyneuropathy? ( 29603302 )
2018
25
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. ( 29122523 )
2018
26
Chronic inflammatory demyelinating polyneuropathy: evaluation of the vestibular system with cervical and ocular vestibular evoked myogenic potentials. ( 29700616 )
2018
27
Chronic inflammatory demyelinating polyneuropathy in adult T-cell leukemia-lymphoma patients following allogeneic stem cell transplantation. ( 30038356 )
2018
28
Resistance training and aerobic training improve muscle strength and aerobic capacity in chronic inflammatory demyelinating polyneuropathy. ( 28345260 )
2018
29
Outcome in chronic inflammatory demyelinating polyneuropathy from a Malaysian centre over sixteen years. ( 29398193 )
2018
30
Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy. ( 29541543 )
2018
31
Reductions in muscle quality and quantity in chronic inflammatory demyelinating polyneuropathy patients assessed by magnetic resonance imaging. ( 29742800 )
2018
32
Hereditary neuropathy with liability to pressure palsies mimicking chronic inflammatory demyelinating polyneuropathy. ( 30017102 )
2018
33
Conventional and unconventional therapies in typical and atypical chronic inflammatory demyelinating polyneuropathy with different clinical course of progression. ( 30027593 )
2018
34
Remission of chronic inflammatory demyelinating polyneuropathy after hepatitis C virus eradication with sofosbuvir and ledipasvir therapy. ( 30028899 )
2018
35
Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany. ( 30073683 )
2018
36
Multifocal visual evoked potentials in chronic inflammatory demyelinating polyneuropathy. ( 30128319 )
2018
37
Nerve ultrasound can distinguish chronic inflammatory demyelinating polyneuropathy from demyelinating diabetic sensorimotor polyneuropathy. ( 30145079 )
2018
38
Assessing the benefit of treatment in chronic inflammatory demyelinating polyneuropathy: the challenges of clinical practice. ( 30223714 )
2018
39
Association of neurofascin IgG4 and atypical chronic inflammatory demyelinating polyneuropathy: A systematic review and meta-analysis. ( 30240176 )
2018
40
Nerve Ultrasound, Electrophysiological, and Clinical Changes in Treatment-Naive Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report. ( 30260816 )
2018
41
Short-term and long-term effects of immunoadsorption in refractory chronic inflammatory demyelinating polyneuropathy: a prospective study in 17 patients. ( 30293110 )
2018
42
Chronic inflammatory demyelinating polyneuropathy: considerations for diagnosis, management, and population health. ( 30312032 )
2018
43
The economic burden and managed care implications of chronic inflammatory demyelinating polyneuropathy. ( 30312033 )
2018
44
Intravenous immunoglobulin for treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy in France: are daily practices in accordance with guidelines? ( 30326184 )
2018
45
New onset psoriasis in a patient with chronic inflammatory demyelinating polyneuropathy treated with Rituximab. ( 30350559 )
2018
46
Missed diagnosis of chronic inflammatory demyelinating polyneuropathy in a patient with cervical myelopathy due to ossification of posterior longitudinal ligament. ( 30370039 )
2018
47
Clinical, Sonographic, and Electrophysiologic Longitudinal Features of Chronic Inflammatory Demyelinating Polyneuropathy. ( 30407676 )
2018
48
Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy. ( 30449785 )
2018
49
Depression with Chronic Inflammatory Demyelinating Polyneuropathy. ( 30533957 )
2018
50
Chronic Inflammatory Demyelinating Polyneuropathy With Concurrent Membranous Nephropathy: An Anti-paranode and Podocyte Protein Antibody Study and Literature Survey. ( 30538665 )
2018

Variations for Demyelinating Polyneuropathy

Expression for Demyelinating Polyneuropathy

Search GEO for disease gene expression data for Demyelinating Polyneuropathy.

Pathways for Demyelinating Polyneuropathy

Pathways related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.79 CNTN2 MAG NFASC NGF
2
Show member pathways
11.43 CNTN1 CNTN2 NFASC
3 11.08 CNTN1 CNTN2 MAG NFASC

GO Terms for Demyelinating Polyneuropathy

Cellular components related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.88 ALB APOA4 HP NGF PTGDS TTR
2 blood microparticle GO:0072562 9.54 ALB APOA4 HP
3 node of Ranvier GO:0033268 9.32 CNTN2 NFASC
4 paranode region of axon GO:0033270 9.26 MAG NFASC
5 compact myelin GO:0043218 9.16 MAG PMP22
6 myelin sheath GO:0043209 9.02 ALB CNTN1 CNTN2 MAG NFASC
7 anchored component of postsynaptic membrane GO:0099025 8.96 CNTN1 CNTN2

Biological processes related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.61 ALB APOA4 TTR
2 receptor-mediated endocytosis GO:0006898 9.58 ALB FCGR2B HP
3 transmission of nerve impulse GO:0019226 9.37 MAG NFASC
4 high-density lipoprotein particle remodeling GO:0034375 9.32 ALB APOA4
5 central nervous system myelination GO:0022010 9.26 CNTN2 MAG
6 protein localization to juxtaparanode region of axon GO:0071205 9.16 CNTN2 NFASC
7 cerebellum development GO:0021549 9.13 AIF1 CNTN1 FCGR2B
8 peripheral nervous system development GO:0007422 8.8 NFASC NGF PMP22

Molecular functions related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.43 CNTN1 CNTN2 MAG
2 lipid binding GO:0008289 9.26 ALB APOA4 FYB1 MAG
3 fatty acid binding GO:0005504 9.16 ALB PTGDS
4 antioxidant activity GO:0016209 8.8 ALB APOA4 HP

Sources for Demyelinating Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....